Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 10/27 10:00:04 pm
115.7 USD   +1.00%
04:52p JOHNSON & JOHNS : Pinnacle Advisory Group buys $1,202,448 stake in J..
03:32p JOHNSON & JOHNS : JNJ) Faces Competition From Mylan Concerta Knockof..
10/26 JOHNSON & JOHNS : to Participate in the 25th Annual Credit Suisse He..
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

share with twitter share with LinkedIn share with facebook
share via e-mail
08/22/2012 | 12:13am CEST
   By Ben Fox Rubin 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
04:52p JOHNSON & JOHNSON : Pinnacle Advisory Group buys $1,202,448 stake in Johnson & J..
03:32p JOHNSON & JOHNSON (NYSE : JNJ) Faces Competition From Mylan Concerta Knockoff
10/26 JOHNSON & JOHNSON : to Participate in the 25th Annual Credit Suisse Health Care ..
10/26 JOHNSON & JOHNSON : Research Reports on Drug Makers Equities -- Pfizer, Merck, A..
10/24 JOHNSON & JOHNSON : Hepatitis B Virus Market (HBV) Review with 2016-2025 Forecas..
10/24 JOHNSON & JOHNSON : Davenport Co buys $162,560,871 stake in Johnson & Johnson
10/24 JOHNSON & JOHNSON : As achievement gap widens, Phoenixville schools seek ways to..
10/22 JOHNSON & JOHNSON : to buy wind power in the US
10/22 JOHNSON & JOHNSON : Carlton Hofferkamp Jenks Wealth Management buys $2,342,903 s..
10/21 JOHNSON & JOHNSON : U.s. fda approves vermox chewable (mebendazole) for treatmen..
More news
Sector news : Pharmaceuticals - NEC
10:29pDJPFIZER : Files 8K - Changes Executive Management
08:35pDJApple Unveils Macs With Touch-Screen Keyboard
07:25p ASTRAZENECA : pauses two cancer drug trials' enrolment due to bleeding
07:15pDJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
07:13pDJBRISTOL MYERS SQUIBB : Makes Moves to Reassure Investors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:51p Should You Buy Pfizer Now?
10/26 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Cree, mcc, reed, erc
10/26 GLOBAL BLOOD THERAPEUTICS : Incredible Value At This Price
10/26 Create Your Own Johnson & Johnson Dividend
10/26 After Positive P2B Results, Tiny, De-Risked Genocea Is Severely Undervalued
Financials ($)
Sales 2016 72 080 M
EBIT 2016 21 940 M
Net income 2016 16 371 M
Finance 2016 19 430 M
Yield 2016 2,74%
P/E ratio 2016 19,38
P/E ratio 2017 17,09
EV / Sales 2016 4,08x
EV / Sales 2017 3,80x
Capitalization 313 422 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results